Basic pharmacology

Cannabidiol and its effects to the adenosinergic system

Published:
2023-07-15
Authors
View
Keywords
License

Copyright (c) 2023 Health Innovation Review

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Az Egészségügyi Innovációs Szemle folyóiratban megjelenő cikkek szabadon megoszthatók, másolhatók az anyagok bármilyen megjelenési formájában a "CC Attribution-NonCommercial-NoDerivatives 4.0" licenszben szereplő szabályok betartásával.

A cikkek változtatás nélkül terjeszthetők, és kereskedelmi felhasználásuk tilos.

How To Cite
Selected Style: APA
Viczján, G., Óvári, I., & Erdei, T. D. (2023). Cannabidiol and its effects to the adenosinergic system. Health Innovation Review, 2(2), 8-13. https://doi.org/10.56626/egis.v2i2.12972
Abstract

Cannabidiol (CBD), the most extensively studied non-intoxicating phytocannabinoid, has been attracting a lot of interest worldwide owing to its numerous beneficial effects. The aim of this review is to describe the various effects of CBD, since it seems to have several molecular targets, acting at which CBD can modify several pathological conditions. CBD has anti-inflammatory, anti-cancer, neuroprotective, anticonvulsant, anxiolytic, antipsychotic, antidepressant, antidiabetic and anti-obesity effects, furthermore it can affect the functions of the adenosinergic system as well.

Regarding myocardial adenosinergic system, CBD is thought to influence two important targets: the A1 adenosine receptor and the equilibrative and nitrobenzylthioinosine-sensitive nucleoside transporter (ENT1 or SLC29A1). ENT1 is a main equilibrative adenosine transporter capable of regulating the interstitial level of adenosine, while the A1 adenosine receptor is a chief protective receptor of the myocardium.